{
    "info": {
        "nct_id": "NCT06657222",
        "official_title": "A Multicenter FIH Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, PK, and Efficacy of the 5T4 ADC TUB-030 in Patients with Advanced Solid Tumors (5-STAR 1-01)",
        "inclusion_criteria": "1. Male or non-pregnant, non-breastfeeding female aged 18 years or older\n2. Adequate organ function\n3. Patients who received anti-cancer treatment including chemotherapy, biological therapy, endocrine therapy, PARP inhibitor, or other oral or investigational drugs must have had their last dose at least 4 weeks (6 weeks for nitrosourea, mitomycin-C) or 5 half-lives, whichever is shorter, before C1D1\n4. AEs related to prior therapy, radiotherapy or surgical procedures must resolve to ≤grade 1.\n5. For patients with known brain metastases, evidence of clinically stable disease post radiation therapy is required prior to enrollment.\n6. For patients who underwent radiotherapy (≥ 30% of the bone marrow or wide field) to sites outside the brain, the final dose of radiation must have been administered ≥ 28 days prior to C1D1. For patients who underwent palliative radiotherapy (≤ 30% of the bone marrow or wide field) the final dose of radiation must have been administered ≥14 days prior to C1D1.\n7. Radiologically measurable disease by RECIST v1.1, 4 weeks before C1D1, that can include a lesion in an irradiated field that shows progression according to RECIST v1.1 after irradiation.\n8. Eastern Cooperative Oncology Group (ECOG) 0-1.\n9. Have a life expectancy of >12 weeks for disease-related mortality, as evaluated by the INV.\n10. In the opinion of the INV, the patient must be able and willing to understand and give signed informed consent\n11. Women of childbearing potential (WOCBP) who are sexually active with a non-sterilized partner must use at least 1 highly effective method of contraception (with a failure rate of 1% per year) from the time of screening and must agree to continue using such precautions until the end of exposure, plus 5 half-lives and 6 months add-on in the case of patients of childbearing potential Patients must agree to continue a highly effective contraceptive method, refrain from egg cell donation and breastfeeding while on study treatment and for 5 half-lives plus 6 months after the last dose of study treatment.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "-",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "8. Eastern Cooperative Oncology Group (ECOG) 0-1.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) 0-1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Adequate organ function",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. AEs related to prior therapy, radiotherapy or surgical procedures must resolve to ≤grade 1.",
            "criterions": [
                {
                    "exact_snippets": "AEs related to prior therapy, radiotherapy or surgical procedures must resolve to ≤grade 1",
                    "criterion": "adverse events related to prior therapy, radiotherapy or surgical procedures",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Have a life expectancy of >12 weeks for disease-related mortality, as evaluated by the INV.",
            "criterions": [
                {
                    "exact_snippets": "life expectancy of >12 weeks for disease-related mortality",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 12,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "disease-related mortality"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Male or non-pregnant, non-breastfeeding female aged 18 years or older",
            "criterions": [
                {
                    "exact_snippets": "Male or non-pregnant, non-breastfeeding female",
                    "criterion": "sex and reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "non-pregnant, non-breastfeeding female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "aged 18 years or older",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. For patients with known brain metastases, evidence of clinically stable disease post radiation therapy is required prior to enrollment.",
            "criterions": [
                {
                    "exact_snippets": "patients with known brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of clinically stable disease post radiation therapy is required prior to enrollment",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "disease stability after radiation therapy",
                            "expected_value": "clinically stable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Women of childbearing potential (WOCBP) who are sexually active with a non-sterilized partner must use at least 1 highly effective method of contraception (with a failure rate of 1% per year) from the time of screening and must agree to continue using such precautions until the end of exposure, plus 5 half-lives and 6 months add-on in the case of patients of childbearing potential Patients must agree to continue a highly effective contraceptive method, refrain from egg cell donation and breastfeeding while on study treatment and for 5 half-lives plus 6 months after the last dose of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential (WOCBP)",
                    "criterion": "sex and reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must use at least 1 highly effective method of contraception (with a failure rate of 1% per year) from the time of screening ... must agree to continue using such precautions until the end of exposure, plus 5 half-lives and 6 months add-on",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "method effectiveness",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "% per year"
                            }
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "from screening until end of exposure, plus 5 half-lives and 6 months"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients must agree to continue a highly effective contraceptive method",
                    "criterion": "contraception use (agreement)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "refrain from egg cell donation",
                    "criterion": "egg cell donation",
                    "requirements": [
                        {
                            "requirement_type": "refrain",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "refrain from ... breastfeeding while on study treatment and for 5 half-lives plus 6 months after the last dose of study treatment",
                    "criterion": "breastfeeding",
                    "requirements": [
                        {
                            "requirement_type": "refrain",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "while on study treatment and for 5 half-lives plus 6 months after last dose"
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Radiologically measurable disease by RECIST v1.1, 4 weeks before C1D1, that can include a lesion in an irradiated field that shows progression according to RECIST v1.1 after irradiation.",
            "criterions": [
                {
                    "exact_snippets": "Radiologically measurable disease by RECIST v1.1",
                    "criterion": "disease measurability by RECIST v1.1",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "RECIST v1.1"
                        }
                    ]
                },
                {
                    "exact_snippets": "4 weeks before C1D1",
                    "criterion": "timing of disease assessment",
                    "requirements": [
                        {
                            "requirement_type": "time before C1D1",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "a lesion in an irradiated field that shows progression according to RECIST v1.1 after irradiation",
                    "criterion": "lesion progression in irradiated field",
                    "requirements": [
                        {
                            "requirement_type": "progression after irradiation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "RECIST v1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Patients who received anti-cancer treatment including chemotherapy, biological therapy, endocrine therapy, PARP inhibitor, or other oral or investigational drugs must have had their last dose at least 4 weeks (6 weeks for nitrosourea, mitomycin-C) or 5 half-lives, whichever is shorter, before C1D1",
            "criterions": [
                {
                    "exact_snippets": "Patients who received anti-cancer treatment including chemotherapy, biological therapy, endocrine therapy, PARP inhibitor, or other oral or investigational drugs must have had their last dose at least 4 weeks (6 weeks for nitrosourea, mitomycin-C) or 5 half-lives, whichever is shorter, before C1D1",
                    "criterion": "prior anti-cancer treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment types",
                            "expected_value": [
                                "chemotherapy",
                                "biological therapy",
                                "endocrine therapy",
                                "PARP inhibitor",
                                "other oral or investigational drugs"
                            ]
                        },
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "time since last dose for nitrosourea, mitomycin-C",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "time since last dose alternative",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "time since last dose rule",
                            "expected_value": "whichever is shorter (between weeks or half-lives) before C1D1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. In the opinion of the INV, the patient must be able and willing to understand and give signed informed consent",
            "criterions": [
                {
                    "exact_snippets": "the patient must be able ... to understand ... informed consent",
                    "criterion": "ability to understand informed consent",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "the patient must be ... willing to ... give signed informed consent",
                    "criterion": "willingness to give signed informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "the patient must be able ... to ... give signed informed consent",
                    "criterion": "ability to give signed informed consent",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. For patients who underwent radiotherapy (≥ 30% of the bone marrow or wide field) to sites outside the brain, the final dose of radiation must have been administered ≥ 28 days prior to C1D1. For patients who underwent palliative radiotherapy (≤ 30% of the bone marrow or wide field) the final dose of radiation must have been administered ≥14 days prior to C1D1.",
            "criterions": [
                {
                    "exact_snippets": "patients who underwent radiotherapy (≥ 30% of the bone marrow or wide field) to sites outside the brain, the final dose of radiation must have been administered ≥ 28 days prior to C1D1",
                    "criterion": "radiotherapy to sites outside the brain (≥ 30% of bone marrow or wide field)",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "site",
                            "expected_value": "outside the brain"
                        },
                        {
                            "requirement_type": "extent",
                            "expected_value": [
                                ">= 30% of the bone marrow",
                                "wide field"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "patients who underwent palliative radiotherapy (≤ 30% of the bone marrow or wide field) ... the final dose of radiation must have been administered ≥14 days prior to C1D1",
                    "criterion": "palliative radiotherapy (≤ 30% of bone marrow or wide field)",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "intent",
                            "expected_value": "palliative"
                        },
                        {
                            "requirement_type": "extent",
                            "expected_value": [
                                "<= 30% of the bone marrow",
                                "wide field"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "-",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}